RELMADA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $355.11M
- P/E (TTM)
- –
- Dividend yield
- –
About Relmada Therapeutics
Pharmaceutical Preparations, SIC 2834
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company that develops pharmaceutical therapies for oncology and central nervous system disorders. The company focuses on two lead development candidates: NDV-01, an intravesical controlled-release combination of gemcitabine and docetaxel for non-muscle-invasive bladder cancer, and sepranolone, a synthetic neurosteroid targeting conditions associated with excessive GABAergic activity, such as Prader-Willi syndrome and Tourette syndrome. Because its drug candidates remain in clinical testing and have not received regulatory approval, the company does not sell commercial products or serve paying customers.
The company conducts development activities primarily in the United States and has clinical trials in Israel. It holds worldwide rights to its oncology candidate, excluding Israel, India, and South Africa. Relmada maintains no commercial sales, marketing, or manufacturing infrastructure and operates from its corporate headquarters in Coral Gables, Florida.
Summary of the business section of Relmada Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RELMADA THERAPEUTICS, INC.
- Headquarters
- Coral Gables, FL
- Address
- 2222 Ponce De Leon Blvd. 3rd Floor 33134
- Phone
- (646) 876-3459
- Website
- relmada.com
- Employees
- 17, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Houston, Texas
Stock & identifiers
- Ticker
- RLMD
- Exchange
- Nasdaq
- IPO date
- Jun 20, 2014
- Shares outstanding
- 107M, Aug 4, 2026
- Public float
- $18.89M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Nov 13, 2019; 1-for-4 reverse, Sep 30, 2019; 1-for-5 reverse, Sep 11, 2015; 1-for-5 reverse, Aug 12, 2015
- SEC CIK
- 1553643
- CUSIP
- 75955J402
- ISIN
- US75955J4022
- LEI
- 549300217EASRZ9JSF81
- EIN
- 45-5401931
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | 1,500,000 |
| Paul Edward Kelly | COO, Director | 502,295 |
| Maged Shenouda | Chief Financial Officer | 1,000,000 |
| Chuck Ence | CA and CO | 403,931 |
| Charles J. Casamento | Director | 10,000 |
| John Glasspool | Director | 75,000 |
| Fabiana Fedeli | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Sergio Traversa | $8.89M | $19.46M | $5.63M | $15 | – |
| FY2024 Sergio Traversa | $1.80M | -$699.23K | $988.40K | $2 | – |
| FY2023 Sergio Traversa | $2.07M | $174.35K | $1.18M | $13 | – |
| FY2022 | $3.19M | -$21.45M | $2.01M | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 17 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 12, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 27, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 8, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 17, 2018 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 14, 2014 | Name change | Name changed from CAMP NINE, INC. to RELMADA THERAPEUTICS, INC. |
| May 27, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 27, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 14, 2014 | Late filing | Notification of late filing |
| Nov 26, 2013 | Late filing | Notification of late filing |